0 CHECKOUT

Epidermolysis Bullosa - Pipeline Review, H1 2015

  • ID: 3280634
  • May 2015
  • 57 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Fibrocell Science, Inc.
  • GlaxoSmithKline plc
  • Scioderm, Inc.
  • Shire Plc
  • TWi Pharmaceuticals, Inc.
  • MORE

Epidermolysis Bullosa - Pipeline Review, H1 2015

Summary

This, ‘Epidermolysis Bullosa - Pipeline Review, H1 2015’, provides an overview of the Epidermolysis Bullosa’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Epidermolysis Bullosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epidermolysis Bullosa and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Fibrocell Science, Inc.
  • GlaxoSmithKline plc
  • Scioderm, Inc.
  • Shire Plc
  • TWi Pharmaceuticals, Inc.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Epidermolysis Bullosa Overview
Therapeutics Development
Pipeline Products for Epidermolysis Bullosa - Overview
Pipeline Products for Epidermolysis Bullosa - Comparative Analysis
Epidermolysis Bullosa - Therapeutics under Development by Companies
Epidermolysis Bullosa - Therapeutics under Investigation by Universities/Institutes
Epidermolysis Bullosa - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Epidermolysis Bullosa - Products under Development by Companies
Epidermolysis Bullosa - Products under Investigation by Universities/Institutes
Epidermolysis Bullosa - Companies Involved in Therapeutics Development
Fibrocell Science, Inc.
GlaxoSmithKline plc
InMed Pharmaceuticals Inc.
RegeneRx Biopharmaceuticals, Inc.
Scioderm, Inc.
Shire Plc
TWi Pharmaceuticals, Inc.
Epidermolysis Bullosa - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
diacerein - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate Collagen Type VII for Recessive Dystrophic Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GMHDFCOL-7 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ICX-RHY - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INM-750 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RGN-137 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SD-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SHP-608 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epidermolysis Bullosa - Recent Pipeline Updates
Epidermolysis Bullosa - Dormant Projects
Epidermolysis Bullosa - Discontinued Products
Epidermolysis Bullosa - Product Development Milestones
Featured News & Press Releases
Mar 19, 2015: Scioderm Initiates Phase 3 Registration Trial of Zorblisa (SD-101), a Novel Topical Therapy for Patients with Epidermolysis Bullosa
Mar 10, 2015: TWi Biotechnology Receives Rare Disease Drug Designation for its Drug Candidate AC-203 in Taiwan
Feb 03, 2015: InMed Expands Pipeline with Initiation of Program Targeting Epidermolysis bullosa simplex
Jan 02, 2015: Scioderm to Present at 33rd Annual J.P. Morgan Healthcare Conference
Oct 21, 2014: TWi Biotechnology Receives Orphan Drug Designation for its Lead Drug Candidate AC-201 In United States
Oct 06, 2014: Scioderm to Present Data from Phase 2b Study of Zorblisa (SD-101) at the 13th Annual BIO Investor Forum
Sep 09, 2014: Scioderm to Present Data from Phase 2b Study of Zorblisa (SD-101) at the debra International Congress
Jul 23, 2014: Fibrocell Science Takes Active Role to Support Dystrophic Epidermolysis Bullosa Patient Advocacy Group
Jun 13, 2014: Fibrocell Science Receives Orphan Drug Designation for Genetically-Modified Autologous Human Fibroblasts to Advance Treatment Development for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
May 28, 2014: Fibrocell Science Announces Plans for Process Development and Manufacturing of Genetically-modified Cell Therapy for Rare Disease, RDEB
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Epidermolysis Bullosa, H1 2015
Number of Products under Development for Epidermolysis Bullosa - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Epidermolysis Bullosa - Pipeline by Fibrocell Science, Inc., H1 2015
Epidermolysis Bullosa - Pipeline by GlaxoSmithKline plc, H1 2015
Epidermolysis Bullosa - Pipeline by InMed Pharmaceuticals Inc., H1 2015
Epidermolysis Bullosa - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2015
Epidermolysis Bullosa - Pipeline by Scioderm, Inc., H1 2015
Epidermolysis Bullosa - Pipeline by Shire Plc, H1 2015
Epidermolysis Bullosa - Pipeline by TWi Pharmaceuticals, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Epidermolysis Bullosa Therapeutics - Recent Pipeline Updates, H1 2015
Epidermolysis Bullosa - Dormant Projects, H1 2015
Epidermolysis Bullosa - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Epidermolysis Bullosa, H1 2015
Number of Products under Development for Epidermolysis Bullosa - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

- Fibrocell Science, Inc.
- GlaxoSmithKline plc
- InMed Pharmaceuticals Inc.
- RegeneRx Biopharmaceuticals, Inc.
- Scioderm, Inc.
- Shire Plc
- TWi Pharmaceuticals, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Cache

Our Clients

  • Merck & Co., Inc.
  • Celgene Corporation
  • GlaxoSmithKline PLC
  • Genentech, Inc.
  • Johnson & Johnson Services, Inc.
  • ViiV Healthcare